Tag: Cancer: Lung
Differences Found in Smokers, Nonsmokers Who Develop NSCLC
Nonsmokers more likely than smokers to be women and to have adenocarcinoma
CT Scans for Lung Cancer Result in Few False-Positives
Concerns that wider adoption of the screen might lead to unnecessary surgeries are unfounded
New Treatment Option for Some With Metastatic Lung Cancer
Nivolumab found most effective in tumors expressing programmed death-ligand 1
Many Pulmonologists Under-, Over-Screen With LDCT
Under-screeners more likely to cite potential harms as influential factors, less influenced by evidence
Novel Prediagnostic Biomarker ID’d for Non-Small-Cell Lung CA
Diacetylspermine identified as serum biomarker; has additive performance with pro-surfactant protein B
Nonsmokers Account for Rising Proportion of Lung Cancer Cases
U.S. and U.K. studies highlight the increasing prevalence of lung cancer in never-smokers
Limited Resection Generally Not Equivalent in Stage IA NSCLC
Only segmentectomy equivalent to lobectomy for older patients with adenocarcinoma
Accuracy, Timing of Pre-Op Lung CA Evaluation Can Be Improved
Most patients have pre-op CT scans; 88 percent have no invasive preoperative staging
Telomere Length May Help Predict Lung Cancer Risk
No significant association seen between telomere length and other types of cancer
![Iressa (gefitinib) has been approved by the U.S. Food and Drug Administration to treat patients with metastatic non-small-cell lung cancer with a specific genetic mutation (epidermal growth factor receptor [EGFR]). A just-approved companion diagnostic test can identify patients who could benefit from this new use.](https://www.ehealth-news.com/wp-content/uploads/2016/01/fdalogo-6-180x84.jpg "FDA Approves Iressa for EGFR+ Metastatic Lung Cancer")
FDA Approves Iressa for EGFR+ Metastatic Lung Cancer
New companion diagnostic kit can identify candidates
